References
- 1. Swerdlow S, Campo E, Harris N. WHO Classification of Tumours of hematopoietic and Lymphoid Tissues, 4th edition, Lyon, France, IARC Press, 2008.
- 2. Pereg D, Koren G, Lishner M. The treatment of Hodgkin’s and non Hodgkin’s lymphoma in pregnancy. Hematologica. 2007;92(09):1230-37.10.3324/haematol.1109717666365
- 3. Smith SM, Vose JM. Treatment approach to diffuse large B-cell lymphomas. In O’Brien S., Vose J.M., Kantarjian H.M. Management of Hematologic Malignancies. Cambridge University Press, 2011:286-307.10.1017/CBO9780511781926.016
- 4. Baldissera RC, Nucci M, Vigorito AC. Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non- Hodgkin's lymphoma patients: a prospective randomized GEMOH report. Acta Haematol. 2006;115:15-21.10.1159/00008946016424644
- 5. Sieniawski M, Staak O, Glossmann JP. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Hematol. 2007;86:107-15.10.1007/s00277-006-0210-517103169
- 6. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507-16.10.1182/blood-2007-06-09723817709603
- 7. Branson K, Chopra R, Kottaridis PD- Role of nonmyeloablative allogeneic stem-cell transplantation in patients with lymphoproliferative malignancies. J Clin Oncol. 2002;20:4022-31.10.1200/JCO.2002.11.08812351600